<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Prokidney Corp. — News on 6ix</title>
<link>https://6ix.com/company/prokidney-corp</link>
<description>Latest news and press releases for Prokidney Corp. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 25 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/prokidney-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b0a678dffbe2df10fc4f.webp</url>
<title>Prokidney Corp.</title>
<link>https://6ix.com/company/prokidney-corp</link>
</image>
<item>
<title>ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer</title>
<link>https://6ix.com/company/prokidney-corp/news/prokidney-expands-senior-leadership-team-with-appointment-of-greg-madison-as-chief-commercial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/prokidney-corp/news/prokidney-expands-senior-leadership-team-with-appointment-of-greg-madison-as-chief-commercial-officer</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>Veteran commercial executive brings deep nephrology and specialty biopharma leadership experience as ProKidney advances rilparencel toward potential</description>
</item>
<item>
<title>ProKidney Reports Full Year 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/prokidney-corp/news/prokidney-reports-full-year-2025-financial-results-and-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/prokidney-corp/news/prokidney-reports-full-year-2025-financial-results-and-business-highlights</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2</description>
</item>
<item>
<title>ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/prokidney-corp/news/prokidney-present-44th-annual-j-123000978</link>
<guid isPermaLink="true">https://6ix.com/company/prokidney-corp/news/prokidney-present-44th-annual-j-123000978</guid>
<pubDate>Tue, 06 Jan 2026 12:30:00 GMT</pubDate>
<description>WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell...</description>
</item>
<item>
<title>ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates</title>
<link>https://6ix.com/company/prokidney-corp/news/prokidney-reports-third-quarter-2025-financial-results-and-provides-regulatory-and</link>
<guid isPermaLink="true">https://6ix.com/company/prokidney-corp/news/prokidney-reports-third-quarter-2025-financial-results-and-provides-regulatory-and</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology</description>
</item>
<item>
<title>ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025</title>
<link>https://6ix.com/company/prokidney-corp/news/prokidney-presents-full-results-phase-2-regen-007-trial-rilparencel-american-society</link>
<guid isPermaLink="true">https://6ix.com/company/prokidney-corp/news/prokidney-presents-full-results-phase-2-regen-007-trial-rilparencel-american-society</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>In patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically significant and clinically</description>
</item>
<item>
<title>ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/prokidney-corp/news/prokidney-participate-two-upcoming-conferences-guggenheim-healthcare-innovation</link>
<guid isPermaLink="true">https://6ix.com/company/prokidney-corp/news/prokidney-participate-two-upcoming-conferences-guggenheim-healthcare-innovation</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>WINSTON-SALEM, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular</description>
</item>
<item>
<title>ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025</title>
<link>https://6ix.com/company/prokidney-corp/news/prokidney-announces-two-abstracts-selected-presentation-american-society-nephrologys</link>
<guid isPermaLink="true">https://6ix.com/company/prokidney-corp/news/prokidney-announces-two-abstracts-selected-presentation-american-society-nephrologys</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular</description>
</item>
<item>
<title>ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference</title>
<link>https://6ix.com/company/prokidney-corp/news/prokidney-participate-two-upcoming-conferences-citi-biopharma-back-school-conference</link>
<guid isPermaLink="true">https://6ix.com/company/prokidney-corp/news/prokidney-participate-two-upcoming-conferences-citi-biopharma-back-school-conference</guid>
<pubDate>Wed, 27 Aug 2025 04:00:00 GMT</pubDate>
<description>WINSTON-SALEM, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular</description>
</item>
<item>
<title>ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates</title>
<link>https://6ix.com/company/prokidney-corp/news/prokidney-reports-second-quarter-2025-financial-results-and-provides-regulatory-and</link>
<guid isPermaLink="true">https://6ix.com/company/prokidney-corp/news/prokidney-reports-second-quarter-2025-financial-results-and-provides-regulatory-and</guid>
<pubDate>Tue, 12 Aug 2025 04:00:00 GMT</pubDate>
<description>FDA confirmed at a July 2025 Type B meeting and in the subsequent meeting minutes that eGFR slope is an acceptable surrogate endpoint for accelerated approval</description>
</item>
<item>
<title>ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel</title>
<link>https://6ix.com/company/prokidney-corp/news/prokidney-announces-alignment-fda-accelerated-approval-pathway-rilparencel-2025-07-15</link>
<guid isPermaLink="true">https://6ix.com/company/prokidney-corp/news/prokidney-announces-alignment-fda-accelerated-approval-pathway-rilparencel-2025-07-15</guid>
<pubDate>Tue, 15 Jul 2025 04:00:00 GMT</pubDate>
<description>FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also</description>
</item>
<item>
<title>ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference</title>
<link>https://6ix.com/company/prokidney-corp/news/prokidney-participate-hc-wainwright-4th-annual-kidney-virtual-conference-2025-07-09</link>
<guid isPermaLink="true">https://6ix.com/company/prokidney-corp/news/prokidney-participate-hc-wainwright-4th-annual-kidney-virtual-conference-2025-07-09</guid>
<pubDate>Wed, 09 Jul 2025 04:00:00 GMT</pubDate>
<description>WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular</description>
</item>
<item>
<title>ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes</title>
<link>https://6ix.com/company/prokidney-corp/news/prokidney-reports-statistically-and-clinically-significant-topline-results-phase-2</link>
<guid isPermaLink="true">https://6ix.com/company/prokidney-corp/news/prokidney-reports-statistically-and-clinically-significant-topline-results-phase-2</guid>
<pubDate>Tue, 08 Jul 2025 04:00:00 GMT</pubDate>
<description>Full results from REGEN-007 are being held and will be submitted to the American Society of Nephrology 2025 Kidney Week as a late-breaking clinical trialIn</description>
</item>
<item>
<title>ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware</title>
<link>https://6ix.com/company/prokidney-corp/news/prokidney-corp-completes-domestication-cayman-islands-delaware-2025-07-01</link>
<guid isPermaLink="true">https://6ix.com/company/prokidney-corp/news/prokidney-corp-completes-domestication-cayman-islands-delaware-2025-07-01</guid>
<pubDate>Tue, 01 Jul 2025 04:00:00 GMT</pubDate>
<description>WINSTON-SALEM, N.C., July 01, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular</description>
</item>
<item>
<title>ProKidney Reports First Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/prokidney-corp/news/prokidney-reports-first-quarter-2025-financial-results-and-business-highlights-2025</link>
<guid isPermaLink="true">https://6ix.com/company/prokidney-corp/news/prokidney-reports-first-quarter-2025-financial-results-and-business-highlights-2025</guid>
<pubDate>Mon, 12 May 2025 04:00:00 GMT</pubDate>
<description>Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025FDA previously confirmed in a Q4 2024 Type B meeting that the accelerated approval</description>
</item>
<item>
<title>ProKidney Reports Full Year 2024 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/prokidney-corp/news/prokidney-reports-full-year-2024-financial-results-and-business-highlights-2025-03-17</link>
<guid isPermaLink="true">https://6ix.com/company/prokidney-corp/news/prokidney-reports-full-year-2024-financial-results-and-business-highlights-2025-03-17</guid>
<pubDate>Mon, 17 Mar 2025 04:00:00 GMT</pubDate>
<description>Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel’s path to market in the U.S., the release of positive</description>
</item>
<item>
<title>ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/prokidney-corp/news/prokidney-present-43rd-annual-jp-morgan-healthcare-conference-2025-01-07</link>
<guid isPermaLink="true">https://6ix.com/company/prokidney-corp/news/prokidney-present-43rd-annual-jp-morgan-healthcare-conference-2025-01-07</guid>
<pubDate>Tue, 07 Jan 2025 05:00:00 GMT</pubDate>
<description>WINSTON-SALEM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the</description>
</item>
<item>
<title>ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference</title>
<link>https://6ix.com/company/prokidney-corp/news/prokidney-participate-two-upcoming-conferences-evercore-healthconx-conference-and</link>
<guid isPermaLink="true">https://6ix.com/company/prokidney-corp/news/prokidney-participate-two-upcoming-conferences-evercore-healthconx-conference-and</guid>
<pubDate>Tue, 26 Nov 2024 05:00:00 GMT</pubDate>
<description>WINSTON-SALEM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the</description>
</item>
<item>
<title>ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting</title>
<link>https://6ix.com/company/prokidney-corp/news/prokidney-reports-third-quarter-2024-financial-results-along-regulatory-and-clinical</link>
<guid isPermaLink="true">https://6ix.com/company/prokidney-corp/news/prokidney-reports-third-quarter-2024-financial-results-along-regulatory-and-clinical</guid>
<pubDate>Tue, 12 Nov 2024 05:00:00 GMT</pubDate>
<description>FDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory</description>
</item>
<item>
<title>ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference</title>
<link>https://6ix.com/company/prokidney-corp/news/prokidney-participate-guggenheim-inaugural-healthcare-innovation-conference-and</link>
<guid isPermaLink="true">https://6ix.com/company/prokidney-corp/news/prokidney-participate-guggenheim-inaugural-healthcare-innovation-conference-and</guid>
<pubDate>Tue, 05 Nov 2024 05:00:00 GMT</pubDate>
<description>WINSTON-SALEM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the</description>
</item>
<item>
<title>ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024</title>
<link>https://6ix.com/company/prokidney-corp/news/prokidney-announces-five-abstracts-selected-presentation-american-society-nephrologys</link>
<guid isPermaLink="true">https://6ix.com/company/prokidney-corp/news/prokidney-announces-five-abstracts-selected-presentation-american-society-nephrologys</guid>
<pubDate>Mon, 14 Oct 2024 04:00:00 GMT</pubDate>
<description>WINSTON-SALEM, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular</description>
</item>
</channel>
</rss>